Inflammation and Activated Innate Immunity in the Pathogenesis of Type 2 Diabletes

Diabetes Care

Volumn 27, Issue 3, 2004, Pages 813-823

  Pickup, John C ^a  

^a GUY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; CYTOKINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PRAVASTATIN;

ACUTE PHASE RESPONSE; ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; DEPRESSION; DRUG ACTIVITY; DYSLIPIDEMIA; FATIGUE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; IMMUNITY; INFLAMMATION; LOW BIRTH WEIGHT; MENTAL STRESS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOGENESIS; REVIEW; SLEEP DISORDER; SMOKING;

DIABETES MELLITUS, TYPE 2; HUMANS; IMMUNITY, NATURAL; INFLAMMATION; MODELS, BIOLOGICAL; STRESS, PSYCHOLOGICAL;

EID: 1442275317     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.27.3.813     Document Type: Review

References (136)

1. Pickup JC, Mattock MB, Chusney GD, Burt D: NIDDM as a disease of the innate immune system: association of acute phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 40:1286-1292, 1997
2. Pickup JC, Crook MA: Is type II diabetes mellitus a disease of the innate immune system? Diabetologia 41:1241-1248, 1998
3. Schmidt MI, Duncan BB, Sharrett AR, Lindberg G, Savage PJ, Offenbacher S, Azambuja MI, Tracey RP, Heiss G: Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. Lancet 353:1649-1652, 1999
4. Duncan BB, Schmidt MI, Offenbacher S, Wu KK, Savage PJ, Heiss G: Factor VIII and other hemostasis variables are related to incident diabetes in adults: The Atherosclerosis Risk in Communities (ARIC) study. Diabetes Care 22:767-772, 1999
5. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM: C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286:327-334, 2001
6. Barzilay JI, Abraham L, Heckbert SR, Cushman M, Kuller LH, Resnick HE, Tracey RP: The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study. Diabetes 50:2384-2389, 2001
7. Vozarova B, Weyer C, Lindsay RS, Pratley RE, Bogardus C, Tataranni PA: High white blood cell count is associated with a worsening of insulin sensitivity and predicts the development of type 2 diabetes. Diabetes 51:455-461, 2002
8. Festa A, D'Agostino R, Tracey RP, Haffner SM: Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the Insulin Resistance Atherosclerosis Study. Diabetes 51:1131-1137, 2002
9. Freeman DJ, Norrie J, Caslake MJ, Gaw A, Ford I, Lowe GDO, O'Reilly DSJ, Packard CJ, Sattar N: C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes 51:1596-1600, 2002
10. Ford ES: Leukocyte count, erythrocyte sedimentation rate, and diabetes incidence in a national sample of US adults. Am J Epidemiol 155:57-64, 2002
11. Nakanishi N, Yoshida H, Matsuo Y, Suzuki K, Tatara K: White blood-cell count and the risk of impaired fasting glucose or type II diabetes in middle-aged Japanese men. Diabetologia 45:42-48, 2002
12. Snijder MB, Dekker JM, Visser M, Stehouwer CDA, van Hinsberg VWM, Bouter LM, Heine RJ: C-reactive protein and diabetes mellitus type 2. Diabetologia 44 (Suppl. 1):115A, 2001
13. Spranger J, Kroke A, Möhlig M, Hoffman K, Bergman MM, Ristow M, Boeing H, Pfeiffer AFH: Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam study. Diabetes 52:812-817, 2003
14. Thorand B, Lowel H, Schneider A, Kolb H, Frohlich M, Koenig W: C-reactive protein as a predictor for incident diabetes mellitus among middle-aged men: results from the MONICA Augsburg cohort study. Arch Intern Med 163:93-99, 2003
15. Medzhitov R, Janeway C: Innate immunity. N Engl J Med 343:338-344, 2000
16. Fearon DT: Seeking wisdom in innate immunity. Nature 388:323-324, 1997
17. Medzhitov R: Toll-like receptors and innate immunity. Nat Rev Immunol 1:135-145, 2001
18. Pearson AM: Scavenger receptors in innate immunity. Curr Opin Immunol 8:20-28, 1996
19. Li YM, Mitsuhashi T, Wojciechowicz D, Shimizu N, Li J, Stitt A, He C, Banerjee D, Vlassara H: Molecular identity and cellular distribution of advanced glycation endproduct receptors: relationship of p60 to OST-48 and p90-80K-H membrane proteins. Proc Natl Acad Sci U S A 93:11047-11052, 1996
20. Medzhitov R, Janeway CA: Decoding the patterns of self and nonself by the innate immune system. Science 296:298-300, 2002
21. Cone JB: Inflammation. Am J Surg 182:558-562, 2001
22. Baumann H, Gauldie J: The acute phase response. Immunol Today 15:74-80, 1994
23. Steel DM, Whitehead AS: The major acute phase reactants: C-reactive protein, serum amyloid P component and serum amyloid A protein. Immunol Today 15:81-87, 1994
24. Gabay C, Kushner I: Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 340:448-454, 1999
25. Sternberg EM: The stress response and the regulation of inflammatory disease. Ann Intern Med 117:854-866, 1992
26. Chrousos GP, Gold PW: The concepts of stress and stress system disorders. JAMA 267:1244-1252, 1992
27. Black PH: Stress and the inflammatory response: a review of neurogenic inflammation. Brain Behav Immun 16:622-653, 2002
28. Crook MA, Tutt P, Simpson H, Pickup JC: Serum sialic acid and acute phase proteins in type 1 and 2 diabetes. Clin Chim Acta 219:131-138, 1993
29. Cabana VG, Siegel JN, Sabesin SM: Effects of the acute phase response on the concentration and density distribution of plasma lipids and apolipoproteins. J Lipid Res 30:39-49, 1989
30. Spiegel R, Schaffer EJ, Magrath IT, Edwards BK: Plasma lipid alterations in leukemia and lymphoma. Am J Med 72:775-782, 1982
31. Olsson AG: Non-atherosclerotic disease and lipoprotein. Curr Opin Lipidol 2:206-210, 1991
32. Yudkin JS, Stehouwer CDA, Emeis JJ, Coppack SW: C-reactive protein in healthy subjects: association with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from the adipose tissue? Arterioscler Thromb Vasc Biol 19:972-978, 1999
33. Fröhlich M, Imhof A, Berg G, Hutchinson WL, Pepys MB, Boeing H, Muche R, Brenner H, Koenig W: Association between C-reactive protein and features of the metabolic syndrome: a population-based study. Diabetes Care 23:1835-1839, 2000
34. Festa A, D'Agostino R, Howard G, Mykkänen L, Tracey RP, Haffner SM: Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 101:42-47, 2000
35. Sakkinen PA, Wahl P, Cushman M, Lewis MR, Tracey RP: Clustering of procoagulation, inflammation and fibrinolysis variables with metabolic factors in insulin resistance syndrome. AmJ Epidemiol 152:897-907, 2000
36. Weyer C, Yudkin JS, Stehouwer CD, Schalkwijk CG, Pratley RE, Tataranni PA: Humoral markers of inflammation and endothelial dysfunction in relation to adiposity and in vivo insulin action in Pima Indians. Atherosclerosis 161:233-242, 2002
37. Ford ES: Body mass index, diabetes, and C-reactive protein among US adults. Diabetes 22:1971-1977, 1999
38. Ford ES: Diabetes and serum ferritin concentration among US adults. Diabetes Care 22:1978-1983, 1999
39. Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB: Elevated C-reactive protein levels in overweight and obese adults. JAMA 282:2131-2135, 1999
40. Hak EA, Pols HA, Stehouwer CDA, Meijer J, Kiliaan AJ, Hofman A, Breteler MMB, Witteman JCM: Markers of inflammation and cellular adhesion molecules in relation to insulin resistance in nondiabetic elderly: the Rotterdam Study. J Clin Endocr Metab 86:4398-4405, 2001
41. Müller S, Martin S, Koenig W, Hanifi-Moghaddam P, Rathmann W, Haastert B, Giani G, Illig T, Thorand B, Kolb H: Impaired glucose tolerance is associated with increased serum concentrations of interleukin 6 and co-regulated acute-phase proteins but not TNF-α or its receptors. Diabetologia 45:805-812, 2002
42. Temelkova-Kurktschiev T, Siegert G, Bergmann S, Henkel E, Koehler C, Jaross W, Hanefield M: Subclinical inflammation is strongly related to insulin resistance but not insulin secretion in a high risk population for diabetes. Metabolism 51:743-749, 2002
43. Temelkova-Kurktschiev T, Henkel E, Koehler C, Karrei K, Hanefield M: Subclinical inflammation in newly detected type II diabetes and impaired glucose tolerance. Diabetologia 45:151, 2002
44. Sriharan M, Reichelt AJ, Opperman ML, Duncan BB, Mengue SS, Crook MA, Schmidt MI: Total sialic acid and associated elements of the metabolic syndrome in women with and without previous gestational diabetes. Diabetes Care 25:1331-1335, 2002
45. Rodriguez-Morán M, Guerrero-Romero F: Increased levels of C-reactive protein in noncontrolled type II diabetic subjects. J Diabetes Complications 13:211-215, 1999
46. Arnalich F, Hernanz A, Lopez-Maderuelo D, Camacho J, Madero R, Vazquez JJ, Montiel C: Enhanced acute-phase response and oxidative stress in older adults with type II diabetes. Horm Metab Res 32:407-412, 2000
47. Leinonen E, Hurt-Camejo E, Wiklund O, Hultén LM, Hiukka A, Taskinen M-R: Insulin resistance and adiposity correlate with acute-phase reaction and soluble cell adhesion molecules in type 2 diabetes. Atherosclerosis 166:387-394, 2003
48. Richardson AP, Tayek JA: Type 2 diabetic patients may have a mild form of an injury response: a clinical research center study. Am J Physiol 282:E1286-E1290, 2002
49. Katsuki A, Sumida Y, Murashima S, Murata K, Takarada Y, Ito K, Fujii M, Tsuchihashi K, Goto H, Nakatani K, Yano Y: Serum levels of tumor necrosis factor-α are increased in obese patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 83:859-862, 1998
50. Winkler G, Salamon F, Salamon D, Speer G, Simon K, Cseh K: Elevated tumour necrosis factor alpha levels can contribute to the insulin resistance in type II (non-insulin-dependent) diabetes and obesity. Diabetologia 41:860-862, 1998
51. Pickup JC, Chusney GC, Thomas SM, Burt D: Plasma interleukin-6, tumor necrosis factor alpha and blood cytokine production in types 2 diabetes. Life Sci 67:291-300, 2000
52. Han TS, Sattar N, Williams K, Gonzalez-Villapando C, Lean MEJ, Haffner SM: Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care 25:2016-2021, 2002
53. Lindsay RS, Funahashi T, Hanson RL, Matsuzawa Y, Tanaka S, Tatarranni PA, Knowler WC, Krakoff J: Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 360:57-58, 2002
54. Libby P, Ridker PM, Maseri A: Inflammation and atherosclerosis. Circulation 105:1135-1143, 2002
55. Binder CJ, Chang M-K, Shaw PX, Miller YI, Hartvigsen K, Dewan A, Witztum JL: Innate and acquired immunity in atherosclerosis. Nat Med 8:1218-1226, 2002
56. Ridker PM, Cushman M, Stamfer MJ, Tracy RP, Hennekens CH: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336:973-979, 1997
57. Ridker PM, Hennekens CH, Buring JE, Rifai N: C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342:836-843, 2000
58. Lindberg G, Eklund G, Gullberg B, Rastam L: Serum sialic acid concentration and cardiovascular mortality. BMJ 302:143-146, 1991
59. Blake GJ, Ridker PM: Inflammatory biomarkers and cardiovascular risk prediction. J Intern Med 252:283-294, 2002
60. Pickup JC, Mattock MB, Crook MA, Chusney GD, Burt D, Fitzgerald AP: Serum sialic acid concentration and coronary heart disease in NIDDM. Diabetes Care 18:1100-1103, 1995
61. Pickup JC, Mattock MB: Activation of the innate immune system as a predictor of cardiovascular mortality in type 2 diabetes mellitus. Diabet Med 20:723-726, 2003
62. Jarrett RJ: Type 2 (non-insulin-dependent), diabetes mellitus and coronary heart disease: chicken, egg or neither? Diabetologia 26:99-102, 1984
63. Pasceri V, Willerson JT, Yeh ET: Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 102:2165-2168, 2000
64. Pasceri V, Cheng JS, Willerson JT, Yeh ET, Chang J: Modulation of C-reactive protein mediated monocyte chemoattractant protein-1 induction by anti-atherosclerotic drugs. Circulation 103:2531-2534, 2001
65. Zwaka TP, Hombach V, Torzewski J: C-reactive protein-mediated low density lipoprotein uptake by macrophages. Circulation 103:1194-1197, 2001
66. Lagrand WK, Niessen HW, Wolbink GJ, Jaspars LH, Visser CA, Verheugt FW, Meijer CJ, Hack CE: C-reactive protein colocalizes with complement in human hearts during acute myocardial infarction. Circulation 95:97-103, 1997
67. Griselli M, Herbert J, Hutchinson WL, Taylor KM, Sohail M, Krausz T, Pepys MB: C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. J Exp Med 190:1733-1740, 1999
68. Ebstein W: Zur therapie des diabetes mellitus insbesondere uber die anwedung des salicylsauren natron bei demselben. Berl Klin Wochenschr 13:337-340, 1877
69. Yuan M, Konstanopoulos N, Lee J, Hansen L, Li Z-W, Karin M, Shoelson SE: Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of ikkβ. Science 293:1673-1677, 2001
70. Hundal RS, Petersen KF, Mayerson AB, Randhawa PS, Inzucchi S, Shoelsen SE, Shulman GI: Mechanism by which highdose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest 109:1321-1326, 2002
71. Freeman DJ, Norrie J, Naveed S, Neely DG, Cobbe SM, Ford I, Isles C, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ, Shepherd J, Gaw A: Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 103:357-362, 2001
72. Weitz-Schmidt G: Statins as anti-inflammatory agents. Trends Pharmacol Sci 23:482-486, 2002
73. Munford RS: Statins and the acute-phase response. N Engl J Med 344:2016-2018, 2001
74. McFarlane SI, Muniyappa R, Fransisco R, Stowers JR: Pleiotropic effects of statins: lipid reduction and beyond. J Clin Endocrinol Metab 87:1451-1458, 2002
75. Ridker PM, Rifai N, Pfeiffer MA, Sacks F, Braunwald E: Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation 100:230-235, 1999
76. Tan KCB, Chow WS, Tam SCF, Ai VHG, Lam CHL, Lam KSL: Atorvastatin lowers C-reactive protein and improves endothelium-dependent vasodilatation in type 2 diabetes mellitus. J Clin Endocrinol Metab 87:563-568, 2002
77. Murphy GJ, Holder JC: PPAR-γ agonists: therapeutic role in diabetes, inflammation and cancer. Trends Pharmacol Sci 21:469-474, 2000
78. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK: The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature 391:79-82, 1998
79. Jiang C, Ting AT, Seed B: PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature 391:82-85, 1998
80. Rosenson RS, Tangney CC, Casey LC: Inhibition of proinflammatory cytokine production by pravastatin. Lancet 353:983-984, 1999
81. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI: Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 106:679-684, 2002
82. Chu NV, Kong APS, Kim DD, Armstrong D, Baxi S, Deutsch R, Caulfield M, Mudaliar SR, Reitz R, Henry RR, Reaven PD: Differential effects of metformin and troglitazone on cardiovascular risk factors with type 2 diabetes. Diabetes Care 25:542-549, 2002
83. Ebeling P, Teppo A-M, Koistinen HA, Viikari J, Rönnemaa T, Nissén M, Bergkulla, Salmela P, Saltevo J, Koivisto VA: Troglitazone reduces hyperglycaemia and selectively acute-phase proteins in patients with type II diabetes. Diabetologia 42:1433-1438, 1999
84. Van de Ree MA, Huisman MV, Princen HMG, Meinders AE, Kluft C: Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes mellitus. Atherosclerosis 166:129-135, 2003
85. Dandona P, Aliada A: A rational approach to pathogenesis and treatment of type 2 diabetes mellitus, insulin resistance, and atherosclerosis. Am J Cardiol 90:27G-33G, 2002
86. Sacks G, Sargent I, Redman C: An innate view of human pregnancy. Immunol Today 20:114-118, 1999
87. Wolf M, Sandler L, Hsu K, Vossen-Smimakis K, Ecker JL, Thadhani R: First-trimester C-reactive protein and subsequent gestational diabetes. Diabetes Care 26:819-825, 2003
88. Morfis MF: Insulin receptor signalling and regulation. In Textbook of Diabetes. 3rd ed. Pickup JC, Williams G, Eds. Oxford, U.K., Blackwell, 2003, p. 14.1-14.17
89. Tanaka T, Itoh H, Doi K, Fukunaga K, Shintani M, Yamashita J, Chun T-H, Inoue M, Masatsugu K, Sawada N, Saito T, Nishimura H, Yoshimasa Y, Nakao K: Down regulation of peroxisome proliferator-activated receptor γ expression by inflammatory cytokines and its reversal by thiazolidinediones. Diabetologia 42:702-710, 1999
90. Steensberg A, Fischer CP, Sacchetti M, Keller C, Osada T, Schjerling P, van Hall G, Febbraio MA, Klarlund Pedersen B: Acute interleukin-6 administration does not impair muscle glucose uptake or whole-body glucose disposal in healthy humans. J Physiol 548:631-638, 2003
91. Thompson D, Harrison SP, Evans SW, Whicher JT: Insulin modulation of acute phase protein production in a human hepatoma cell line. Cytokine 3:619-626, 1991
92. Campos SP, Baumann H: Insulin is a prominent modulator of the cytokine-stimulated expression of acute-phase plasma protein genes. Mol Cell Biol 12:1789-1797, 1992
93. Pickup JC, Day C, Bailey CJ, Samuel A, Chusney GD, Garland HO, Hamilton K, Balment RJ: Plasma sialic acid in animal models of diabetes mellitus: evidence for modulation of sialic acid concentrations by insulin deficiency. Life Sci 57:1383-1391, 1995
94. Phillips DI, Walker BR, Reynolds RM, Flanagan DE, Wood PJ, Osmond C, Barker DJ: Low birth weight predicts elevated plasma cortisol concentrations' in adults from 3 populations. Hypertension 35:1301-1306, 2000
95. Barker DJP: Fetal origins of coronary heart disease. BMJ 311:171-174, 1995
96. Fernandez-Real JM, Gutierrez C, Ricart W, Casamitjana R, Fernandez-Castaner M, Vendrell J, Richart C, Soler JL: The TNF-alpha gene Nco I polymorphism influences the relationship among insulin resistance, percent body fat, and increased serum leptin levels. Diabetes 46:1468-1472, 1997
97. Day CP, Grove J, Daly AK, Stewart MW, Avery PJ, Walker M: Tumour necrosis factor alpha gene promoter polymorphism and decreased insulin resistance. Diabetologia 41:430-434, 1998
98. Fernández-Real J-M, Vendrell J, Ricart W, Broach M, Gutiérrez C, Casamitjana R, Oriola J, Richart C: Polymorphism of the tumor necrosis factor-a receptor 2 gene is associated with obesity, leptin levels, and insulin resistance in young subjects and diet-treated type 2 diabetic patients. Diabetes Care 23:831-837, 2000
99. Fernández-Real J-M, Broch M, Vendrell J, Gutiérrez C, Casamitjana R, Pugeat M, Richart C, Ricart W: Interleukin-6 gene polymorphism and insulin sensitivity. Diabetes 49:517-520, 2000
100. Pannacciulli N, De Pergola G, Giorgino F, Giogino R: A family history of type 2 diabetes is associated with increased plasma levels of C-reactive protein in non-smoking healthy women. Diabet Med 19:689-692, 2002
101. Pickup JC, Chana T, Mattock MB, Samuel A, Mather HM: Serum sialic acid concentrations in Asian diabetic patients in the UK. Diabet Med 13:284-285, 1996
102. Grimble RF: Nutrition and cytokine action. Nutr Res Rev 3:193-210, 1990
103. Endres S, Ghorbani R, Kelley VE, Georgilis K, Lonnemann G, van der Meer JW, Cannon JG, Rogers TS, Klempner MS, Weber PC, et al.: The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. N Engl J Med 320:265-271, 1989
104. Orban Z, Remaley AT, Sampson M, Trajanoski Z, Chrousas GP: The differential effect of food intake and beta-adrenergic stimulation on adipose-derived hormones and cytokines in man. J Clin Endocrinol Metab 84:2126-2133, 1999
105. Upritchard JE, Sutherland WHF, Mann JI: Effect of supplementation with tomato juice, Vitamin E, and vitamin C on LDL oxidation and products of inflammatory activity in type 2 diabetes. Diabetes Care 23:733-738, 2000.
106. Vlassara H, Cai W, Crandall J, Goldberg T, Oberstein R, Dardaine V, Peppa M, Rayfield EJ: Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proc Natl Acad Sci U S A 99:15596-15601, 2002
107. Fagiolo U, Cossarizza A, Scala E, Fanales-Belasio E, Ortolani C, Cozzi E, Monti D, Franceschi C, Paganelli R: Increased cytokine production in mononuclear cells of healthy elderly people. Eur J Immunol 23:2375-2378, 1993
108. Caswell M, Pike LA, Bull BS, Stuart J: Effect of age on tests of the acute-phase response. Arch Pathol Lab Med 117:906-910, 1993
109. Bruunsgaard H, Pedersen M, Klarland Pedersen B: Aging and proinflammatory cytokines. Curr Opin Hematol 8:131-136, 2001
110. Francesci C, Bonafe M, Valensin S, Olivieri F, De Luca M, Ottaviani E, DeBenedictis G: Inflamm-aging: an evolutionary perspective on immunosenescence. Ann N Y Acad Sci 908:244-254, 2000
111. Lindberg G, Råstam L, Gullberg B, Eklund GA, Tömberg S: Serum sialic acid concentration and smoking: a population based study. BMJ 303:1306-1307, 1991
112. Abramson JL, Vaccarino V: Relationship between physical activity and inflammation among apparently healthy middle-aged and older US adults. Arch Intern Med 162:1286-1292, 2002
113. Wannamethee SG, Lowe GD, Whincup PH, Rumley A, Walker M, Lennon L: Physical activity and hemostatic and inflammatory variables in elderly men. Circulation 105:1758-1790, 2002
114. Wales JK: Does psychological stress cause diabetes? Diabet Med 12:109-112, 1995
115. Surwit RS, Schneider MS, Feinglos MN: Stress and diabetes mellitus. Diabetes Care 15:1413-1422, 1992
116. Osler W: The Principles and Practice of Medicine. New York, Appleton, 1892
117. Mooy JM, de Vries H, Grootenhuis PA, Bouter LM, Heine RJ: Major stressful life events in relation to prevalence of undetected type 2 diabetes: the Hoorn Study. Diabetes Care 23:197-201, 2000
118. Sapolsky RM, Krey LC, McEwen BS: The neuroendocrinology of aging: the glucocorticoid cascade hypothesis. Endocr Rev 7:284-301, 1986
119. McEwen BS, Seeman T: Protective and damaging effects of mediators of stress: elaborating and testing the concepts of allostasis and allostatic load. Ann N Y Acad Sci 896:30-47, 1999
120. Lindsay S, Krakoff J, Hanson RL, Bennett PH, Knowler WC: Gamma globulin levels predict type 2 diabetes in the Pirna Indian population. Diabetes 50:1598-1603, 2001
121. Cseh K, Baranyi E, Winkler G: The role of the innate and adaptive immune system in the regulation of insulin resistance. Diabetologia 42:497-498, 1999
122. Yoo JY, Desiderio S: Innate and acquired immunity intersect in a global view of the acute-phase response. Proc Natl Acad Sci U S A 100:1157-1162, 2003
123. Ceriello A, Mercuri F, Fabbro D, Giacomello R, Stel G, Taboga C, Tonutti L, Motz E, Damante G: Effect of intensive glycaemic control on fibrinogen plasma concentrations in patients with type II diabetes mellitus: relation with β-fibrinogen genotype. Diabetologia 41:1270-1273, 1998
124. Morohoshi M, Fujisawa K, Uchimura I, Numano F: Glucose-dependent interleukin-6 and tumor necrosis factor production by human peripheral blood monocytes in vitro. Diabetes 45:954-959, 1996
125. Vlassara H, Brownlee M, Montague KR, Dinarello C, Pasagian A: Cachectin/TNF and IL-1 induced by glucose modified proteins: role in normal tissue modeling. Science 240:1546-1548, 1988
126. Esposito K, Nappo F, Marfella R, Giugliano G, Giugliano F, Ciotola M, Qaugliaro L, Ceriello A, Guigliano D: Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation 106:2067-2072, 2002
127. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM: Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 95:2409-2415, 1995
128. Mohamed-Ali V, Goodrick S, Rawesh A, Mile JM, Katz DR, Yudkin JS, Coppack SW: Human subcutaneous adipose tissue releases IL6 but not TNF-alpha in vivo. J Clin Endocrinol Metab 82:4196-4200, 1997
129. Fried SK, Bunkin DA, Greenberg AS: Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: adipose tissue difference and regulation by glucocorticoid. J Clin Endocrinol Metab 83:847-850, 1998
130. Krakoff J, Funnahashi T, Stehouwer CD, Schalkwijk CG, Tanaka S, Matsuzawa Y, Kobes S, Tataranni PA, Hanson RL, Knowler WC, Lindsay RS: Inflammatory markers, adiponectin, and risk of type 2 diabetes in the Pima Indian. Diabetes Care 26:1745-1751, 2003
131. Stuart J, George AG, Davies AJ, Auklund A, Hurlow RA: Haematological stress syndrome in atherosclerosis. J Clin Pathol 34:464-467, 1981
132. Dessein PH, Stanwix AE, Joffe BI: Cardiovascular risk in rheumatoid arthritis versus osteoarthritis: acute phase response related to decreased insulin sensitivity and high-density lipoprotein cholesterol, as well as clustering of metabolic syndrome features in rheumatoid arthritis. Arthritis Res 4:R5, 2002
133. Nichols GA, Brown JB: Unadjusted and adjusted prevalence of diagnosed depression in type 2 diabetes. Diabetes Care 26:744-749, 2003
134. Leonard BE: Changes in the immune system in depression and dementia: causal or co-incidental effects? Int J Dev Neurosci 19:305-312, 2001
135. Vgontzas AN, Papanicolaou DA, Bixler EO, Hopper K, Lotsikas A, Lin H-M, Kales A, Chrousas GP: Sleep apnea and daytime sleepiness and fatigue: relation to visceral obesity, insulin resistance and hypercytokinemia. J Clin Endocrinol Metab 85:1151-1158, 2000
136. Inui A: Cytokines and sickness behaviour: implications from knockout animal models. Trends Immunol 22:469-473, 2001